Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA orders Bristol-Myers’ Opdivo to the sidelines on 3 studies as regulators explore dangers of checkpoint combos
FDA orders Bristol-Myers’ Opdivo to the sidelines on 3 studies as regulators explore dangers of checkpoint combos
FDA orders Bristol-Myers’ Opdivo to the sidelines on 3 studies as regulators explore dangers of checkpoint combos
Submitted by
admin
on September 6, 2017 - 8:57pm
Source:
Endpoints
News Tags:
FDA
Bristol-Myers Squibb
Opdivo
clinical trials
Multiple Myeloma
Headline:
FDA orders Bristol-Myers’ Opdivo to the sidelines on 3 studies as regulators explore dangers of checkpoint combos
Do Not Allow Advertisers to Use My Personal information
